Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Supernus Pharmaceuticals Inc

CUSIP: 868459908 | 9 institutional holders

Quarters

Q3 2026 Q2 2026 Q1 2026 Q3 2025 Q2 2025

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile